VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent research report by Aegis Capital Corp. The report reads, “VistaGen is developing multiple therapeutic candidates for the treatment of anxiety, depression, and other CNS indications. VistaGen’s development pipeline includes PH94B, a neuroactive nasal spray targeting Social Anxiety Disorder (‘SAD’), among other conditions, PH10, an additional neuroactive nasal spray for indications including Major Depressive Disorder (‘MDD’), and AV-101 an oral drug for psychiatric and other CNS disorders. We believe Phase 2 data in PH94B and PH10 strongly supports proof of concept, including compelling safety and efficacy data that likely differentiate these assets from existing treatments in crucial ways that could be supportive of market adoption if and when approved.”
To view the full report, visit https://ibn.fm/eLamD
About VistaGen Therapeutics
VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
